National Institute of Allergy and Infectious Diseases (NIAID)
Middle East respiratory syndrome coronavirus (MERS-CoV) viral particles under an electron microscopic.
“This is looking across coronaviruses and finding the commonalities so we’re in a better position to attack SARS3 when it comes,” said Nevan Krogan, the director of QBI.
Danica Galonić Fujimori, PhD, will receive $1.25 million in funding over the next five years from the endowment of the late William K. Bowes, Jr., a venture capitalist and longtime UCSF supporter.
The antiviral invented by Aashish Manglik, PhD, and colleagues is effective at blocking SARS-CoV-2 infection even as an aerosolized spray, according to laboratory testing.
School scientists developed an antiviral that fights SARS-CoV-2 that can be given as a nasal spray.
Nevan Krogan, PhD (standing), leads a meeting of the QBI Coronavirus Research Group with fellow UCSF faculty members (seated from left) Danica Galonic Fujimori, PhD; Natalia Jura, PhD; James Fraser, PhD; and David Agard, PhD.
The QBI Coronavirus Research Group found six drugs that effectively beat back SARS-COV-2 in the laboratory.
